HOME ·

R&D Progress

SBP GROUP (01177.HK): Preclinical Data of Oral STAT6 Degrader TQH5528 Presented at ERS 2026
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-08
FOSUN PHARMA (02196.HK): FXS5626 Approved for Phase II/III Trial in Non-Segmental Vitiligo
Tags：
FOSUN PHARMA02196.HKR&D Progress
2026-09-08
UNITED LAB (03933.HK): UBT251 injection completes first participant dosing in Phase III clinical study for type 2 diabetes in China
Tags：
UNITED LAB03933.HKR&D Progress
2026-09-07
MICROTECH MED-B (02235.HK): Next-generation CGM AiDEX G9 obtains NMPA registration approval for marketing
Tags：
MICROTECH MED-B02235.HKR&D Progress
2026-09-07
SBP GROUP (01177.HK): Phase I data of TQC3721 dry powder inhaler (PDE3/4 inhibitor) presented at ERS 2026, showing dose-dependent lung function improvement in COPD
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-07
TENNOR THERAP-B (06872.HK): Positive Phase IIa Proof-of-Concept Data for Rifaquizalone (TNP-2092) in Prosthetic Joint Infection; Multicenter Phase IIb Initiated
Tags：
TENNOR THERAP-B06872.HKR&D Progress
2026-09-07
KINTOR PHARMA-B (09939.HK): Long-Term Safety Trial of KT-939 Completed; No Skin Adverse Reactions in 114 Subjects Over 52 Weeks
Tags：
KINTOR PHARMA-B09939.HKR&D Progress
2026-09-07
CLOVER BIO-B (02197.HK): Positive Phase II Data for Respiratory Combo Vaccine Candidates in Australian Elderly
Tags：
CLOVER BIO-B02197.HKR&D Progress
2026-09-07
HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for oral GLP-1 weight-loss drug HRS-7535 tablets
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-04
SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China
Tags：
SIMCERE PHARMA02096.HKR&D Progress
2026-09-04
SBP GROUP (01177.HK): FDA Approves IND Application for Self-Developed Class 1 Drug TQB6426 "GPC3 ADC" for Advanced Malignant Tumors
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-03
CMS (00867.HK): China NDA Approval for Ruxolitinib Phosphate Cream in Atopic Dermatitis Adds a Second Indication
Tags：
CMS00867.HKR&D Progress
2026-09-03
CMS (00867.HK): Opzelura-Counterpart Baicor (Ruxolitinib Cream) Approved for Atopic Dermatitis in China
Tags：
CMS00867.HKR&D Progress
2026-09-03
AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit
Tags：
AKESO09926.HKR&D Progress
2026-09-03
CUTIA-B (02487.HK): BLA for CU-20101 botulinum toxin type A for injection accepted by NMPA
Tags：
CUTIA-B02487.HKR&D ProgressNew Drug Marketing Application
2026-09-03
OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China
Tags：
OCUMENSION-B01477.HKR&D Progress
2026-09-02
HAIXI PHARMA (02637.HK): Oral Retinal Disease Drug HX9428 Files Phase IIa IND for Diabetic Macular Edema; Phase I Data in nAMD Disclosed
Tags：
HAIXI PHARMA02637.HKR&D Progress
2026-09-02
HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
Tags：
HANSOH PHARMA03692.HKR&D Progress
2026-09-02
CSPC PHARMA (01093.HK): ADC candidate SYS6010 receives another Breakthrough Therapy designation in China for recurrent or metastatic head and neck squamous cell carcinoma
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2056 tablets for major depressive disorder officially initiated in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
Previous123 456